Similarly, a study conducted by Cowling et al. in 2017 [20] was the first to demonstrate the therapeutic benefit of DNM2 downregulation in BIN-1-related CNM (i.e., ARCNM). Here, DNM2 is linked to autosomal recessive centronuclear myopathy.